⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ENTA News
Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
businesswire.com
ENTA
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
businesswire.com
ENTA
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026 TM, the Annual Meeting of the American Association of Immunologists (AAI)
businesswire.com
ENTA
Form 8-K
sec.gov
ENTA
Form 8-K
sec.gov
ENTA
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
businesswire.com
ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
businesswire.com
ENTA
ENT & Allergy Associates Welcomes Otolaryngologist Christopher V. Lisi, MD to its West Nyack, NY Office
globenewswire.com
ENTA
Enanta Pharmaceuticals to Present at the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
ENTA
ENT & Allergy Associates Expands Network to Texas by Partnering with Houston ENT & Allergy
globenewswire.com
ENTA